Xinteza Introduces Novel Key Enzyme to Solve Major Bottlenecks in Cannabinoid Biosynthesis
TEL AVIV, Israel, Sept. 8, 2022 /PRNewswire/ -- Xinteza API Ltd., an innovative biosynthesis technology company, announced today the discovery of a new catalytic enzyme, capable of solving one of the major bottlenecks that has so far limited the design of sustainable and cost-efficient cannabinoid biosynthesis production systems, in breakthrough research led by Prof. Asaph Aharoni at the Weizmann Institute of Science.
- As reported previously , Xinteza has recently unveiled discoveries for a patent-pending whole new non-cannabis source of cannabinoid biosynthesis related genes and enzymes.
- This newly discovered gene pool includes a novel prenyl-transferase enzyme, featuring superior kinetics and improved flexibility in introduction into micro-organism-based expression systems.
- "As we expand our IP's commercialization and collaboration activity, we are highly motivated by this pivotal discovery of such a key novel enzyme.
- "We continue to optimize commercial-scale processes of cannabinoid biosynthesis with the most sophisticated proprietary cannabinoid producing genes and enzymes from our growing portfolio", Gal added.